Interleukin 12 gene therapy of MHC-negative murine melanoma metastases

Patrizia Nanni, Ilaria Rossi, Carla De Giovanni, Lorena Landuzzi, Giordano Nicoletti, Antonella Stoppacciaro, Mareilla Parenza, Mario P. Colombo, Pier Luigi Lollini

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Immunological gene therapy of cancer relies heavily on the activation of T cells, but tumors with defects in MHC gene expression are not recognized by MHC-restricted T cells. To investigate the potential of cytokine genes for the therapy of MHC-negative tumors, we transduced B78H1, a class I-negative murine melanoma clone, with a polycistronic vector carrying murine interleukin (IL)-12 genes. The clones studied produced 400-25,000 pg/ml IL- 12; their in vitro growth properties were similar to those of parental cells. A complete inhibition of growth was observed in vivo both after s.c. and i.v. administration of all IL-12 clones. IL-12-transduced cells were also used as a therapeutic vaccine in mice bearing micrometastases by nontransduced parental cells. A significant (80-90%) reduction in the number of lung nodules was obtained. Immunohistochemical analysis and studies in immunocompromised hosts showed that T cells and natural killer cells had a significant role in the elimination of IL-12-releasing cells. In situ hybridization with cytokine probes detected a strong increase in the proportion of leukocytes positive for IFN-γ, tumor necrosis factor α, IL- 1β, and IFN-inducible protein 10 at the site of rejection of IL-12- engineered tumor cells. However, it was clear that the loss of in vivo growth was also due to T-cell- and natural killer cell-independent factors, possibly related to the antiangiogenic properties of IL-12. In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms.

Original languageEnglish
Pages (from-to)1225-1230
Number of pages6
JournalCancer Research
Volume58
Issue number6
Publication statusPublished - Mar 15 1998

Fingerprint

Interleukin-12
Genetic Therapy
Melanoma
Neoplasm Metastasis
Neoplasms
T-Lymphocytes
Clone Cells
Natural Killer Cells
Growth
Cytokines
Neoplasm Micrometastasis
Immunocompromised Host
Interleukin-1
Genes
In Situ Hybridization
Leukocytes
Vaccines
Tumor Necrosis Factor-alpha
Gene Expression
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nanni, P., Rossi, I., De Giovanni, C., Landuzzi, L., Nicoletti, G., Stoppacciaro, A., ... Lollini, P. L. (1998). Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Research, 58(6), 1225-1230.

Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. / Nanni, Patrizia; Rossi, Ilaria; De Giovanni, Carla; Landuzzi, Lorena; Nicoletti, Giordano; Stoppacciaro, Antonella; Parenza, Mareilla; Colombo, Mario P.; Lollini, Pier Luigi.

In: Cancer Research, Vol. 58, No. 6, 15.03.1998, p. 1225-1230.

Research output: Contribution to journalArticle

Nanni, P, Rossi, I, De Giovanni, C, Landuzzi, L, Nicoletti, G, Stoppacciaro, A, Parenza, M, Colombo, MP & Lollini, PL 1998, 'Interleukin 12 gene therapy of MHC-negative murine melanoma metastases', Cancer Research, vol. 58, no. 6, pp. 1225-1230.
Nanni P, Rossi I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Research. 1998 Mar 15;58(6):1225-1230.
Nanni, Patrizia ; Rossi, Ilaria ; De Giovanni, Carla ; Landuzzi, Lorena ; Nicoletti, Giordano ; Stoppacciaro, Antonella ; Parenza, Mareilla ; Colombo, Mario P. ; Lollini, Pier Luigi. / Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. In: Cancer Research. 1998 ; Vol. 58, No. 6. pp. 1225-1230.
@article{6c1802d8037f4ad1be72605cc11fd0b9,
title = "Interleukin 12 gene therapy of MHC-negative murine melanoma metastases",
abstract = "Immunological gene therapy of cancer relies heavily on the activation of T cells, but tumors with defects in MHC gene expression are not recognized by MHC-restricted T cells. To investigate the potential of cytokine genes for the therapy of MHC-negative tumors, we transduced B78H1, a class I-negative murine melanoma clone, with a polycistronic vector carrying murine interleukin (IL)-12 genes. The clones studied produced 400-25,000 pg/ml IL- 12; their in vitro growth properties were similar to those of parental cells. A complete inhibition of growth was observed in vivo both after s.c. and i.v. administration of all IL-12 clones. IL-12-transduced cells were also used as a therapeutic vaccine in mice bearing micrometastases by nontransduced parental cells. A significant (80-90{\%}) reduction in the number of lung nodules was obtained. Immunohistochemical analysis and studies in immunocompromised hosts showed that T cells and natural killer cells had a significant role in the elimination of IL-12-releasing cells. In situ hybridization with cytokine probes detected a strong increase in the proportion of leukocytes positive for IFN-γ, tumor necrosis factor α, IL- 1β, and IFN-inducible protein 10 at the site of rejection of IL-12- engineered tumor cells. However, it was clear that the loss of in vivo growth was also due to T-cell- and natural killer cell-independent factors, possibly related to the antiangiogenic properties of IL-12. In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms.",
author = "Patrizia Nanni and Ilaria Rossi and {De Giovanni}, Carla and Lorena Landuzzi and Giordano Nicoletti and Antonella Stoppacciaro and Mareilla Parenza and Colombo, {Mario P.} and Lollini, {Pier Luigi}",
year = "1998",
month = "3",
day = "15",
language = "English",
volume = "58",
pages = "1225--1230",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Interleukin 12 gene therapy of MHC-negative murine melanoma metastases

AU - Nanni, Patrizia

AU - Rossi, Ilaria

AU - De Giovanni, Carla

AU - Landuzzi, Lorena

AU - Nicoletti, Giordano

AU - Stoppacciaro, Antonella

AU - Parenza, Mareilla

AU - Colombo, Mario P.

AU - Lollini, Pier Luigi

PY - 1998/3/15

Y1 - 1998/3/15

N2 - Immunological gene therapy of cancer relies heavily on the activation of T cells, but tumors with defects in MHC gene expression are not recognized by MHC-restricted T cells. To investigate the potential of cytokine genes for the therapy of MHC-negative tumors, we transduced B78H1, a class I-negative murine melanoma clone, with a polycistronic vector carrying murine interleukin (IL)-12 genes. The clones studied produced 400-25,000 pg/ml IL- 12; their in vitro growth properties were similar to those of parental cells. A complete inhibition of growth was observed in vivo both after s.c. and i.v. administration of all IL-12 clones. IL-12-transduced cells were also used as a therapeutic vaccine in mice bearing micrometastases by nontransduced parental cells. A significant (80-90%) reduction in the number of lung nodules was obtained. Immunohistochemical analysis and studies in immunocompromised hosts showed that T cells and natural killer cells had a significant role in the elimination of IL-12-releasing cells. In situ hybridization with cytokine probes detected a strong increase in the proportion of leukocytes positive for IFN-γ, tumor necrosis factor α, IL- 1β, and IFN-inducible protein 10 at the site of rejection of IL-12- engineered tumor cells. However, it was clear that the loss of in vivo growth was also due to T-cell- and natural killer cell-independent factors, possibly related to the antiangiogenic properties of IL-12. In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms.

AB - Immunological gene therapy of cancer relies heavily on the activation of T cells, but tumors with defects in MHC gene expression are not recognized by MHC-restricted T cells. To investigate the potential of cytokine genes for the therapy of MHC-negative tumors, we transduced B78H1, a class I-negative murine melanoma clone, with a polycistronic vector carrying murine interleukin (IL)-12 genes. The clones studied produced 400-25,000 pg/ml IL- 12; their in vitro growth properties were similar to those of parental cells. A complete inhibition of growth was observed in vivo both after s.c. and i.v. administration of all IL-12 clones. IL-12-transduced cells were also used as a therapeutic vaccine in mice bearing micrometastases by nontransduced parental cells. A significant (80-90%) reduction in the number of lung nodules was obtained. Immunohistochemical analysis and studies in immunocompromised hosts showed that T cells and natural killer cells had a significant role in the elimination of IL-12-releasing cells. In situ hybridization with cytokine probes detected a strong increase in the proportion of leukocytes positive for IFN-γ, tumor necrosis factor α, IL- 1β, and IFN-inducible protein 10 at the site of rejection of IL-12- engineered tumor cells. However, it was clear that the loss of in vivo growth was also due to T-cell- and natural killer cell-independent factors, possibly related to the antiangiogenic properties of IL-12. In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=0032520919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032520919&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 1225

EP - 1230

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -